While Arcutis Biotherapeutics Inc has underperformed by -1.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ARQT rose by 11.20%, with highs and lows ranging from $17.75 to $8.03, whereas the simple moving average jumped by 11.12% in the last 200 days.
On July 25, 2025, Goldman started tracking Arcutis Biotherapeutics Inc (NASDAQ: ARQT) recommending Neutral. A report published by H.C. Wainwright on December 30, 2024, Initiated its previous ‘Buy’ rating for ARQT. Jefferies also rated ARQT shares as ‘Buy’, setting a target price of $15 on the company’s shares in an initiating report dated August 28, 2024. Mizuho January 03, 2024d the rating to Buy on January 03, 2024, and set its price target from $4 to $8. Mizuho October 26, 2023d its ‘Buy’ rating to ‘Neutral’ for ARQT, as published in its report on October 26, 2023. Goldman’s report from October 13, 2023 suggests a price prediction of $6 for ARQT shares, giving the stock a ‘Neutral’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Arcutis Biotherapeutics Inc (ARQT)
Further, the quarter-over-quarter increase in sales is 164.13%, showing a positive trend in the upcoming months.
One of the most important indicators of Arcutis Biotherapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -57.33% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.04, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ARQT is recording 1.77M average volume. On a monthly basis, the volatility of the stock is set at 5.51%, whereas on a weekly basis, it is put at 3.61%, with a loss of -1.90% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.75, showing growth from the present price of $15.49, which can serve as yet another indication of whether ARQT is worth investing in or should be passed over.
How Do You Analyze Arcutis Biotherapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 12.84%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 98.66% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
